LONDON, November 16, 2015 /PRNewswire/ --
Allmed Group is pleased to announce it has acquired a controlling stake in PRONEFRO PRODUTOS NEFROLÓGICOS S.A ("Pronefro"). Pronefro is a bloodlines manufacturer based in Portugal, with a wholly-owned sales, marketing & distribution subsidiary in Brazil, as well as a distribution network in the EMEA region.
Commenting on the acquisition, Ahmed Sorour, Allmed Group's CEO, said: "I am delighted with this exciting acquisition and welcome the entire Pronefro team to Allmed Group. Pronefro was established in 1983 and has a very well respected brand in the bloodlines marketplace for both quality and reliability."
The acquisition of Pronefro is a further component of the future growth strategy of Allmed Group. The acquisition strengthens Allmed Group in key markets, as well as providing an integrated manufacturing facility within the European Union, with substantial expansion capacity. Financial terms were not disclosed.
Pronefro group sales during 2014 were in excess of €4.5 million. Pronefro Portugal has 75 staff members at their manufacturing Plant in Oporto and 13 staff based in Curitiba in central Brazil.
Pronefro Portugal and Brazil will become known as Allmed Pronefro PT and Allmed Pronefro BR, respectively.
About Allmed Group
Allmed Group is global vertically-integrated producer of end-to-end haemodialysis product solutions. It is headquartered in London and has three primary manufacturing operations, two in Germany and one in Egypt. In addition, it has a direct sales, marketing & distribution operations in the UK, Egypt, Poland, Germany and Turkey. Allmed further operates haemodialysis clinics in Central Europe. The Group employs more than 1,600 staff world-wide and exports to more than 40 countries across the globe.
For further information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott or Matthew Neal
SOURCE Allmed Group